Investors & Media

Nasdaq

Investor Relations

For more information and the latest news about Merus N.V., please visit our Investor Relations section by clicking the button below.

[This section of the website is under construction. You will be temporarily re-routed to Merus’ old website.] 

Investors & Media
Stock information
Nasdaq : MRUS (Common Stock)
$17.03
Change : 0.46 2.63%
Volume : 41,667
Market Cap : 330.546M
Data as of April 23, 2018 @ 04:00 pm EST
(Data provided by Nasdaq. Maximum 15 minutes delayed)
UTRECHT, The Netherlands, March 20, 2018 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq:MRUS), a clinical-stage… 
UTRECHT, The Netherlands, March 14, 2018 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing… 
Merus’ First U.S. Patent Covering MCLA-117 and Merus’ Spleen to Screen® Technology for Efficient… 
UTRECHT, The Netherlands, Feb. 14, 2018 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology… 
UTRECHT, the Netherlands, Jan. 26, 2018 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology… 
UTRECHT, Netherlands and NANJING, China, Jan. 08, 2018 (GLOBE NEWSWIRE) — Merus (Nasdaq:MRUS) and Simcere Pharmaceutical Group today announced that Merus… 
UTRECHT, The Netherlands, Jan. 04, 2018 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing… 
UTRECHT, The Netherlands, Jan. 02, 2018 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing… 
MERUS ANNOUNCES THE U.S. COURT OF APPEALS FOR THE FEDERAL CIRCUIT DENIES REGENERON’S PETITION… 
the company's presence in 2018

Upcoming events

Are you interested in meeting the Merus team? Check out where you can find us in 2018 at (international) meetings and events.

All events
Investors & media
Investor

Downloads

Merus discovers and develops differentiated therapeutics aimed at substantially prolonging the lives of cancer patients. It is our strategy to use the power of bispecific antibody engineering and advanced screening technologies to develop biopharmaceuticals that engage the power of the immune system to kill tumor cells.

April 28, 2017
2016 ANNUAL REPORT (20-F), SEC filing
Merus' 2016 Annual Report 20-F form, SEC filing. Registration of securities of foreign private issuers pursuant to section 12(b) or (g), filed on April 28, 2017.
March 15, 2018
March Investor Presentation
Merus Corporate Presentation - March 2018
January 31, 2018
January Investor Presentation
Merus Corporate Presentation - January 2018
June 15, 2017
Biopharma Dealmakers – Merus Profile
Published article "Battling Cancer with Bispecific Antibodies" in BioPharma Dealmakers, June 2017.